EstroTep 500 MBq/mL, solution injectable
IC 2022-12
Phase 3 small_molecule active
Quick answer
EstroTep 500 MBq/mL, solution injectable for Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active